← Product Code [KRH](/submissions/CV/subpart-d%E2%80%94cardiovascular-prosthetic-devices/KRH) · K061127 # CG FUTURE ANNULOPLASTY SYSTEM, MODEL 638R (K061127) _Medtronic Vascular · KRH · May 23, 2006 · Cardiovascular · SESE_ **Canonical URL:** https://fda.innolitics.com/submissions/CV/subpart-d%E2%80%94cardiovascular-prosthetic-devices/KRH/K061127 ## Device Facts - **Applicant:** Medtronic Vascular - **Product Code:** [KRH](/submissions/CV/subpart-d%E2%80%94cardiovascular-prosthetic-devices/KRH.md) - **Decision Date:** May 23, 2006 - **Decision:** SESE - **Submission Type:** Special - **Regulation:** 21 CFR 870.3800 - **Device Class:** Class 2 - **Review Panel:** Cardiovascular - **Attributes:** Therapeutic ## Indications for Use The CG Future® Annuloplasty Ring and Band is indicated for the reconstruction and/or remodeling of pathological mitral valves. Valvular insufficiency and/or stenosis may be corrected by appropriate repair and annular remodeling. ## Device Story CG Future® Annuloplasty Ring is a semi-rigid, D-shaped implant for mitral valve repair. Device consists of a C-shaped metal stiffener covered in silicone and fabric, with ends joined by suture and fabric to form a closed ring. Includes a radiopaque strip for X-ray identification. Provided with a disposable holder for implantation, which interfaces with an annuloplasty handle. Used by surgeons in an operating room setting to remodel the mitral annulus. By providing structural support to the valve annulus, the device facilitates repair of insufficiency or stenosis, potentially improving valve function and patient outcomes. ## Clinical Evidence Bench testing only. Verification and validation studies were conducted to demonstrate that the device modifications are appropriate and do not negatively impact the intended use or performance compared to the predicate devices. ## Technological Characteristics Semi-rigid, D-shaped annuloplasty ring. Materials: metal stiffener, silicone, fabric. Features: radiopaque strip for imaging, disposable holder for implantation. Sterilization: not specified. Connectivity: none. Software: none. ## Regulatory Identification An annuloplasty ring is a rigid or flexible ring implanted around the mitral or tricuspid heart valve for reconstructive treatment of valvular insufficiency. ## Special Controls *Classification.* Class II (special controls). The special control for this device is the FDA guidance document entitled “Guidance for Annuloplasty Rings 510(k) Submissions.” ## Predicate Devices - CG Future® Annuloplasty Band ([K052860](/device/K052860.md)) - Duran AnCore® Ring and Band ([K032810](/device/K032810.md)) ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0}------------------------------------------------ K061127 MAY 2 3 2006 # 510(k) Summary - CG Future® Annuloplasty Ring ## Applicant (Sponsor) Name and Address Medtronic Heart Valves (Medtronic) 8299 Central Avenue N.E. - M.S. 108 Minneapolis, MN 55432 Establishment Reg. No .: 2127690 ## Contact Name and Phone Phil Neururer Regulatory Affairs Specialist Company Phone: (763) 514-6600 Company Fax: (763) 514-6775 #### Device Trade/Proprietary Name CG Future® Annuloplasty Ring (CG Ring) ## Device Classification/Common Name/Panel 21 CFR Reference: 870.3800 21 CFR Common Name: Ring, Annuloplasty Classification: Class II Panel: CV (74) KRH # Identification of Predicate Device Medtronic believes the CG Ring is substantially equivalent to the CG Future® Annuloplasty Band (CG Band) previously cleared to market in the U.S. by FDA on November 10, 2005 (K052860) and also the Duran AnCore® Ring and Band (Duran Product Family) previously cleared to market in the U.S. by FDA on December 5, 2003 (K032810) and may market our device under these equivalencies. ## Substantial Equivalence The CG Ring has the same fundamental scientific technology and intended use as the predicate devices. {1}------------------------------------------------ # Description of Intended Use The CG Ring is indicated for the reconstruction and/or remodeling of pathological mitral valves. Valvular insufficiency and/or stenosis may be corrected by appropriate repair and annular remodeling. # Device Description The Model 638R CG Ring is based on the marketed released Model 638B CG Band and Model 620R/620B Duran Product Family. The CG Ring is a semi-rigid annuloplasty ring intended for remodeling and/or reconstruction of pathological mitral valves. Similar to the CG Ring is composed of a C-shaped metal stiffener that is covered with silicone and fabric. Unlike the CG Future Band but similar to the Duran Product Family, the CG Ring is a fully closed ring, formed by joining the ends of the stiffener with suture and fabric, resulting in a D-shaped device. In addition, a similar radiopaque strip that is used in the Duran Product Family is placed between the stiffener ends for identification of the device on X-ray. The disposable CG Ring Holder provides for attachment of the ring, guides the implantation of the ring, and interfaces with the Model 7615 Annuloplasty Handle. There are eight (8) sizes for the holder (24, 26, 28, 30, 32, 34, 36, and 38 mm), and a single holder is provided with each packaged ring assembly. The CG Ring packaging consists of double-aseptic pouches (containing the ring attached to its holder). The pouch assembly is placed in a shelf carton box along with instructions for use and product traceability labels for shipping. # Performance Data The CG Ring was subjected to verification and validation studies. The verification/validation studies demonstrate that the modifications to the predicated device are appropriate and do not affect the intended use or performance of the device. {2}------------------------------------------------ Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health and Human Services. The logo consists of a stylized eagle or bird-like symbol with three curved lines representing its wings or feathers. The text "DEPARTMENT OF HEALTH AND HUMAN SERVICES. USA" is arranged in a circular fashion around the bird symbol. The logo is in black and white. Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850 MAY 2 3 2006 Mr. Phil Neururer Regulatory Affairs Specialist Medtronic, Incorporated 8299 Central Avenue N.E. Minneapolis, MN 55432 Re: K061127 Trade/Device Name: CG Future® Annuloplasty Ring (CG Ring) Regulation Number: 21 CFR 870.3800 Regulation Name: Annuloplasty Ring Regulatory Class: Class II Product Code: KRH Dated: April 21, 2006 Received: April 24, 2006 Dear Mr. Neururer: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration. Iisting of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set {3}------------------------------------------------ #### Page 2 – Mr. Phil Neururer forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html. Sincerely yours, Bram D. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {4}------------------------------------------------ # 510(k) Number (if known): K06 Device Name: CG Future® Annuloplasty Ring and Band Indications for Use: The CG Future® Annuloplasty Ring and Band is indicated for the reconstruction and/or remodeling of pathological mitral valves. Valvular insufficiency and/or stenosis may be corrected by appropriate repair and annular remodeling. #### (PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE) Prescription Use Per 21 CFR 801.109 OR Over-The-Counter Use ( Division Sign Off) ular Devices --- **Source:** [https://fda.innolitics.com/submissions/CV/subpart-d%E2%80%94cardiovascular-prosthetic-devices/KRH/K061127](https://fda.innolitics.com/submissions/CV/subpart-d%E2%80%94cardiovascular-prosthetic-devices/KRH/K061127) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com